CONCLUSIONS: In Japan, GXR has become an increasingly preferred medication for ADHD, particularly for female patients and children aged 6-12 years, with new prescriptions exceeding those of OROS-MPH since late 2019. This trend may be attributed to GXR not being subject to the same distribution control regulations as central nervous system stimulants and to its distinctive pharmacological mechanisms that differ from those of other ADHD medications. Continuous monitoring of prescription practices…
